Next Generation Therapies: Aortic, Mitral and Beyond
|
|
- Arron Peters
- 5 years ago
- Views:
Transcription
1 Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017
2 Next Generation Therapies: Aortic, Mitral and Beyond
3 Origins of TAVR
4 Severe Symptomatic Aortic Stenosis: 50% 2-year Mortality Severe Symptomatic Aortic Stenosis: Percent Treated AVR No AVR Ross and Braunwald 1968, Circulation Bouma B J et al. Heart 1999;82: Iung B et al. European Heart Journal 2003;24: Pellikka, Sarano et al. Circulation 2005 Charlson E et al. J Heart Valve Dis 2006;15:
5 CORE? STS 0-3 EuroScore 0-2 STS 4-8 EuroScore 3-5 STS > 8 EuroScore > 6 LOW INTERMED HIGH INOPERABLE < 70 yo, no comorbidities 80 years old, no comorbidities 80 years old Prior sternotomy SAVR SAPIEN What 1 o endpoint is appropriate?
6 Challenges to Success in Low-Risk Patients Procedural Considerations Have Greater Relevance Continue to reduce paravalvular leak Continue to reduce vascular complications Continue to reduce incidence of heart block Continue to reduce incidence of stroke Technological Considerations Require Broader Consideration More clinical experience to observe valve durability Valve-in-valve potential Access to coronary arteries
7 SAVR CORE SAPIEN U.S. Low Risk Trials LOW Risk TRIAL DESIGN ENDPOINTS PARTNER III STS < 4% N = Sites 1-yr MORTALITY STROKE REHOSPITALIZATION MDT Low-Risk STS < 3% N = Sites 2-yr MORTALITY STROKE Randomized TAVR v SAVR Both in early enrollment
8 Next Generation Therapies: Aortic, Mitral and Beyond
9 Mitral Valve Therapies European Survey on Valvular Heart Disease 92 Centers, 25 countries over 4 months Those not offered surgery were older, with more co-morbidities (diabetes, atheresclerotic vascular disease, lung disease), heart failure admissions, and overall comorbidity indices. At the time of intervention, comorbidities* may drive outcome more strongly than the valve disease itself.
10 Percutaneous Strategies: MitraClip Prolapse Restricted Motion EVEREST I and II Surgical Candidates COAPT Symptomatic or Asymptomatic RESHAPE-HF MVR Indication 10 Feldman and Young 2014, JACC
11 Percutaneous Strategies: MitraClip Surgical candidates (n = 279), with operative indication. 2:1 MitraClip:Surgery Compared to surgery, MitraClip had: Fewer adverse events (30-d) Comparable mortality Comparable symptomatic improvement Greater residual MR Higher rate of subsequent MV surgery (~20%) The goal of any therapy is simple to live longer or better. Patients with Moderate-Severe Mitral Regurgitation that are Poor Surgical Candidates 11 Feldman et al. 2011, 2015 NEJM; Feldman and Young 2014, JACC
12 MitraClip EVEREST II Trial Primary Endpoint* Freedom from Reoperation After 6-mo Compared to surgery, MitraClip had: Fewer adverse events (30-d) Comparable mortality Comparable symptomatic improvement Greater residual MR Higher rate of subsequent MV surgery (~20%) If procedural outcomes and reduction in residual MR can be improved, might a percutaneous approach be preferred? *Death, mitral valve surgery, 3-4+ mitral regurgitation 12 Feldman et al NEJM
13 MitraClip FDA Approved The MitraClip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation due to primary abnormality of the mitral apparatus (degenerative MR) in patients who are at prohibitive risk for mitral valve surgery. What about Functional Mitral Regurgitation? COAPT Trial 13
14 Direct Mitral Annuloplasty Mitralign (Mitralign Inc) RFA-assisted puncture Place pledgets, draw together Accucinch (Guided Delivery Systems) Anchors below MV Nitinol wire to cinch Cardioband (Edwards) Above MV Sequential Anchors Feldman and Young 2014, JACC
15 Percutaneous Mitral Replacement Structural Considerations Varied pathophysiological states Annulus size, 3-dimensional anatomy Subvalvular apparatus Ventricular size, geometry, function Dynamic pressure environment Technical Considerations Securely fix prosthesis Avoid left ventricular outflow tract Avoid paravalvular leak Manage potential areas of stasis Implantation route and safety
16 SAPIEN Approved for Mitral Valve in Valve Clinical need, innovation Approved based on registry Requires existing bioprosthesis 16
17 Percutaneous Mitral Replacement Twelve (Medtronic) TA delivery Inner/Outer Stent Repositionable CardiaQ (Edwards) TA, TF delivery Supra-annular Repositionable Tendyne (Abbott) TA delivery Tethered to apex Repositionable Tiara (Neovasc) TA delivery Avoids LVOT No anchoring Herrmann 2015, CRF; De Backer et al 2014, Circ Cardiovasc Interv
18 Percutaneous Mitral Replacement Twelve (Medtronic) TA delivery Inner/Outer Stent Repositionable APPOLO Trial Severe symptomatic mitral regurgitation STS > 3% Candidate for bioprosthetic MVR Recruiting now
19 Next Generation Therapies: Aortic, Mitral and Beyond
20 Is the Tricuspid Valve Relevant? Arbulu et al., 1991 J Thorac Cardiovasc Surg 53 patients (IVDA) with right sided endocarditis Valvulectomy without replacement 16 (30%) died, 6 within 45 days 6 (11%) later with valve replacement due to refractory right sided heart failure Some tolerate, so do not 20
21 Tricuspid Regurgitation and Mortality 5,233 patients, TTE at VAMC, 4-year follow up Severe TR: 50% survival at ~2-yrs (47 days) Independent of PA pressures, LV or RV function 21 Nath et al., JACC 2004
22 Strategies for Percutaneous Intervention Cinch, Coapt, or Re-construct Cinch (Annular Reduction) Cerclage Plication Tensioning Re-Construct Valve-in-valve SVC-IVC Valves Coapt MitraClip Forma Anchor 22
23 Strategies for Percutaneous Intervention: Cinch TriAlign (MitrAlign) TriCinch (4Tech) Early US feasibility (SCOUT) *Early CE Mark Trials Hahn et al. 2017; Fortech, TVT
24 Strategies for Percutaneous Intervention: Coapt MitraClip (Abbott) Forma Anchor (Edwards)* ~3:1 AS:PS *Early US feasibility Nickening et al. 2017; Campelo-Parada et al
25 Percutaneous Valve Replacement Native: Caval Valves IVC and/or SVC IVC caliber, landing zone Limited experience NYHA marginally improves Dedicated devices forthcoming Tricuspid Ring: VIV 64 year old female HOVER (US) TRICAVAL (Europe) 25
26 64 year old female Rheumatic Heart Disease 1982: Mitral valve replacement (Porcine) 1991: Mitral valve replacement (Mechanical) 1994: Mitral valve replacement (Mechanical) 1997: Mitral valve replacement (Mechanical), Aortic valve replacement (Mechanical), Tricuspid valve #34 Physio ring and Mitral valve cadaveric homograft in the tricuspid position Congestive cirrhosis, MELD 11, Childs-Pugh Class A NYHA IV, repeated paracenteses
27
28 Conclusions Percutaneous therapies for aortic, mitral and tricuspid valve disease are rapidly developing Heterogeneous population, different expectations Options for transcatheter therapies exist for nearly all patients with valvular heart disease Collaborative and multidisciplinary decision making can lead to the right therapies, for the right patient
29 Thank You Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program scott.lilly@osumc.edu
Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions
Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationTranscatheter Mitral Valve for fmr: The Era of Too Many Options
Transcatheter Mitral Valve for fmr: The Era of Too Many Options Isaac George, M.D. Surgical Director, Structural Heart & Valve Center Assistant Professor of Surgery Columbia University Medical Center Disclosure
More informationPercutaneous mitral valve repair/replacement. Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein
Percutaneous mitral valve repair/replacement Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein Mitral Valve anatomy Difference between AoV and MV Aortic Valve Mitral Valve Transcatheter Mitral
More informationMy Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.
My Choice For Percutaneous Mitral Valve Replacement Jose Luis Navia, MD. Disclosure Edwards Lifescienses St. Jude Medical MAQUET NaviGate Consultant, Investigator Consultant, Investigator Consultant, Investigator
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationEmerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX
Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX Conflict of Interest Disclosure Abbott Vascular- Co PI COAPT Trial Medtronic- Executive Committee
More informationImaging to select patients for Transcatheter TV
Imaging to select patients for Transcatheter TV Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands San Diego, february 2018 Research grants: Medtronic, Biotronik, Boston Scientific,
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationGet Ready for Percutaneous Mitral Valve Approaches
Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationDisclosure Statement of Financial Interest Saibal Kar, MD, FACC
MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
More informationObjectives. Considerations in management of multivalvular disease. Case Discussions. A Systematic Approach to Multivalve Disease.
A Systematic Approach to Multivalve Disease James D. Thomas, MD, FACC, FASE Director, Center for Heart Valve Disease Bluhm Cardiovascular Institute Professor of Medicine, Feinberg School of Medicine, Northwestern
More informationPERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL
PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationTrans-catheter TV repair Leaflet or Annuloplasty Techniques
EuroValve 2018 Palermo, Italy Trans-catheter TV repair Leaflet or Annuloplasty Techniques Corrado Tamburino, MD, PhD Full Professor, University of Catania University Policlinic, Catania FACTS ON TRICUSPID
More informationVALVULOPATIE: NUOVE SOLUZIONI.
VALVULOPATIE: NUOVE SOLUZIONI www.fisiokinesiterapia.biz Nkomo, Lancet 2006 ELDERLY POPULATION PROJECTION IN USA 65-84 Years Old 85 and Older 77,2 Millions of people 34,8 4,3 30,5 53,8 6,8 47 14,3 62,9
More informationPercutaneous mitral valve repair: current techniques and results
Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationUpdate on a Tethered Transapical Device for TMVR Vinay Badhwar, MD
Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute West Virginia
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationTAVI EN INSUFICIENCIA AORTICA
TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES
More informationPercutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?
Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today? Peter S. Fail, MD, FACC, FACP, FSCAI Director of the Cardiac Catheterization Laboratories and Interventional
More informationVinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
More informationCurrent status: Percutaneous mitral valve therapy
Current status: Percutaneous mitral valve therapy Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital ESC Stockholm 2010 Disclosures Research Grants Abbott, Edwards Consultant Abbott, Edwards 2 Percutaneous
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationMITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male
MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis
More informationMitral Programme Update
Direct Flow Medical Innovations in the Aortic and Mitral Programmes Mitral Programme Update Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy Potential conflicts
More informationMitral Regurgitation
Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical
More informationEduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine University of
Catheter Based Treatment of Valvular Heart Disease In the Adult Sping 2016 Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationSergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa
Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa Prevalence of Valvular Disease The Lancet, Vol. 368, Nkomo, V. T. et al., Burden of valvular heart diseases: a population-based
More informationΑνεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας. Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ
Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ Disclosures - Proctoring activities for Abbott Vascular, Edwards Lifesciences I and the HYGEIA Hospital
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More information7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA Mitral Valve Disease Today Mitral regurgitation is the most
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationPercutaneous mitral annuloplasty. Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy
Percutaneous mitral annuloplasty Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy Disclosure Consultant for Abbott, Medtronic, St Jude, Edwards, ValtechCardio Founder of 4Tech Surgical techniques
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationStatus Of The MitraClip: Trials (EVEREST II & COAPT) & FDA
Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationSURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY
SURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research
More informationEulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain
Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non
More informationCite this article as:
doi: 10.21037/acs.2018.09.05 Cite this article as: Cheung A. Early experience of TIARA transcatheter mitral valve replacement system.. doi: 10.21037/acs.2018.09.05 This is a PDF file of an edited manuscript
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationDevelopment of a TMVR Device Challenge to Innovators
Development of a TMVR Device Challenge to Innovators Eberhard Grube MD, FACC, FSCAI, FAPSIC University Bonn, Heart Center, Bonn, Germany Stanford Universuty, School of Medicine, Palo Alto, CA Disclosure
More informationTranscatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.
Transcatheter Mitral Valve Interventions: Clinical Indications Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Conflicts of interest: -Consultant for Medtronic -Consultant for Cephea Anatomy of
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationValvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.
Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationCardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More informationUPDATE STRUKTURELLE INTERVENTIONELLE KARDIOLOGIE
SGK Herbsttagung 17 November 2016, Aarau UPDATE STRUKTURELLE INTERVENTIONELLE KARDIOLOGIE Stephan Windecker Department of Cardiology Swiss Cardiovascular Center Bern University Hospital, Switzerland WHAT
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationDurability of Mitral Valve Surgery: Repair, Replacement or simply a clip? Christoph Huber Chirurgie Cardio Vasculaire HUG
Durability of Mitral Valve Surgery: Repair, Replacement or simply a clip? Christoph Huber Chirurgie Cardio Vasculaire HUG La chirurgie cardiaque innovatrice et durable Mitral valve disease Mitral regurgitation
More informationPercutaneous Transcatheter Treatment of Valvular Disease TAVR and Beyond
Percutaneous Transcatheter Treatment of Valvular Disease TAVR and Beyond CREIGHTON W. DON, MD, PHD ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR, INTERVENTIONAL AND STRUCTURAL HEART FELLOWSHIPS DIVISION OF
More informationJOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis
JOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis Similarities and differences in Tricuspid vs. Mitral Valve Anatomy and Imaging. Echo evaluation
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationTranscatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.
Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationChallenging Case. 77 year old man 1/24/2018. Two months PTA AVR with 21 Edwards Magna and VSD repair for S. Aureus endocarditis
Vumedi January 2018 77 year old man Challenging Case Paul Sorajja, MD Roger L. and Lynn C. Headrick Family Chair Valve Science Center, Minneapolis Heart Institute Foundation Abbott Northwestern Hospital
More informationPercutaneous Mitral Valve Repair
Indiana Chapter of ACC November 15 th,2008 Percutaneous Mitral Valve Repair James B Hermiller, MD, FACC The Care Group, LLC St Vincent Hospital Indianapolis, IN Mechanisms of Mitral Regurgitation Mitral
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationWhen Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea
When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationCite this article as:
doi: 10.21037/acs.2018.10.01 Cite this article as: Beller JP, Rogers JH, Thourani VH, Ailawadi G. Early clinical results with the Tendyne transcatheter mitral valve replacement system. Ann Cardiothorac
More informationMitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN
Mitral Valve Disease James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Disclosures Affiliation/Financial Relationship Consulting Fees/Honoraria Speaker Bureau Company Abbott, BSC,
More informationPercutaneous Treatment of Mitral Insufficiency: Present and Future
Percutaneous Treatment of Mitral Insufficiency: Present and Future Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine Seattle, WA
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationTAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion
TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion Moderator: Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular
More informationPercutaneous Mitral Interventions. Alec Vahanian, FESC, FRCP (Edin.) Bichat Hospital, Paris University Paris VII
Percutaneous Mitral Interventions Alec Vahanian, FESC, FRCP (Edin.) Bichat Hospital, Paris University Paris VII Rationale for Percutaneous Mitral Valve Interventions Mitral valve disease is frequent and
More information